Skip to main content
Favipiravir 200 mg
Product Description
  • A broad-spectrum antiviral with in vitro activity against various viruses, including coronaviruse, approved for emergency use to treat mild and moderate COVID-19 cases.
  • Using favipiravir to treat patients with COVID-19 showed significant clinical outcomes including:
  • Lower incidence of dyspnea.
  • Suitable for concomitant use with corticosteroids.
  • Shorter viral clearance.
  • Improvement in chest imaging.
  • Well-tolerated treatment.
  • Better treatment effects on disease progression.
  • Faster relief for cough and pyrexia.
  • Suitable for use at home.